Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 383

1.

Anxiolytic and antidepressant actions of somatostatin: the role of sst2 and sst3 receptors.

Engin E, Treit D.

Psychopharmacology (Berl). 2009 Oct;206(2):281-9. doi: 10.1007/s00213-009-1605-5. Epub 2009 Jul 17.

PMID:
19609508
2.

Anxiolytic and antidepressant effects of intracerebroventricularly administered somatostatin: behavioral and neurophysiological evidence.

Engin E, Stellbrink J, Treit D, Dickson CT.

Neuroscience. 2008 Dec 2;157(3):666-76. doi: 10.1016/j.neuroscience.2008.09.037. Epub 2008 Oct 2.

PMID:
18940236
3.

Intracerebroventricular injection of somatostatin sst5 receptor agonist inhibits gastric acid secretion in rats.

Martínez V, Coy DH, Lloyd KC, Taché Y.

Eur J Pharmacol. 1996 Jan 25;296(2):153-60.

PMID:
8838451
4.

Anxiolytic-like effects of somatostatin isoforms SST 14 and SST 28 in two animal models (Rattus norvegicus) after intra-amygdalar and intra-septal microinfusions.

Yeung M, Engin E, Treit D.

Psychopharmacology (Berl). 2011 Aug;216(4):557-67. doi: 10.1007/s00213-011-2248-x. Epub 2011 Mar 19.

PMID:
21424237
5.

The anxiolytic effects of somatostatin following intra-septal and intra-amygdalar microinfusions are reversed by the selective sst2 antagonist PRL2903.

Yeung M, Treit D.

Pharmacol Biochem Behav. 2012 Mar;101(1):88-92. doi: 10.1016/j.pbb.2011.12.012. Epub 2011 Dec 22.

PMID:
22210489
6.

ATC0175: an orally active melanin-concentrating hormone receptor 1 antagonist for the potential treatment of depression and anxiety.

Chaki S, Yamaguchi J, Yamada H, Thomsen W, Tran TA, Semple G, Sekiguchi Y.

CNS Drug Rev. 2005 Winter;11(4):341-52. Review.

7.

Anxiolytic-like activity of the non-selective galanin receptor agonist, galnon.

Rajarao SJ, Platt B, Sukoff SJ, Lin Q, Bender CN, Nieuwenhuijsen BW, Ring RH, Schechter LE, Rosenzweig-Lipson S, Beyer CE.

Neuropeptides. 2007 Oct;41(5):307-20. Epub 2007 Jul 16.

PMID:
17637475
8.

Anxiolytic-like profiles of histamine H3 receptor agonists in animal models of anxiety: a comparative study with antidepressants and benzodiazepine anxiolytic.

Yokoyama F, Yamauchi M, Oyama M, Okuma K, Onozawa K, Nagayama T, Shinei R, Ishikawa M, Sato Y, Kakui N.

Psychopharmacology (Berl). 2009 Aug;205(2):177-87. doi: 10.1007/s00213-009-1528-1. Epub 2009 Apr 9.

PMID:
19357839
9.

Drug design at peptide receptors: somatostatin receptor ligands.

Hannon JP, Nunn C, Stolz B, Bruns C, Weckbecker G, Lewis I, Troxler T, Hurth K, Hoyer D.

J Mol Neurosci. 2002 Feb-Apr;18(1-2):15-27. Review.

PMID:
11931345
10.

Differential roles of amygdaloid nuclei in the anxiolytic- and antidepressant-like effects of the V1b receptor antagonist, SSR149415, in rats.

Salomé N, Stemmelin J, Cohen C, Griebel G.

Psychopharmacology (Berl). 2006 Aug;187(2):237-44. Epub 2006 Jun 2.

PMID:
16779555
11.

Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression.

Wesołowska A, Nikiforuk A, Stachowicz K, Tatarczyńska E.

Neuropharmacology. 2006 Sep;51(3):578-86. Epub 2006 Jul 7.

PMID:
16828124
12.

Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models.

Engin E, Treit D, Dickson CT.

Neuroscience. 2009 Jun 30;161(2):359-69. doi: 10.1016/j.neuroscience.2009.03.038. Epub 2009 Mar 24. Erratum in: Neuroscience. 2009 Sep 15;162(4):1438-9.

PMID:
19321151
13.

Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.

Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, Culler M, Ginj M, Liu Q, Schonbrunn A, Reubi JC.

J Nucl Med. 2006 Mar;47(3):502-11.

14.
15.

[New medical treatments in pituitary adenomas].

Drutel A, Caron P, Archambeaud F.

Ann Endocrinol (Paris). 2008 Sep;69 Suppl 1:S16-28. doi: 10.1016/S0003-4266(08)73964-7. Review. French.

PMID:
18954854
16.

Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression.

Gehlert DR, Rasmussen K, Shaw J, Li X, Ardayfio P, Craft L, Coskun T, Zhang HY, Chen Y, Witkin JM.

J Pharmacol Exp Ther. 2009 May;329(2):429-38. doi: 10.1124/jpet.108.143362. Epub 2009 Jan 30.

17.

Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation.

Sørensen G, Lindberg C, Wörtwein G, Bolwig TG, Woldbye DP.

J Neurosci Res. 2004 Sep 1;77(5):723-9.

PMID:
15352219
18.

Behavioral effects of the beta3 adrenoceptor agonist SR58611A: is it the putative prototype of a new class of antidepressant/anxiolytic drugs?

Consoli D, Leggio GM, Mazzola C, Micale V, Drago F.

Eur J Pharmacol. 2007 Nov 14;573(1-3):139-47. Epub 2007 Jul 4.

PMID:
17669397
19.

The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration.

Nikiforuk A, Kos T, Wesołowska A.

Psychopharmacology (Berl). 2011 Oct;217(3):411-8. doi: 10.1007/s00213-011-2297-1. Epub 2011 Apr 16.

PMID:
21499701
20.
Items per page

Supplemental Content

Write to the Help Desk